Ozempic for Weight Loss: Why It Is Prescribed Off-Label and How It Differs From Wegovy

A reader wrote in last month with a question that sounded simple: “My sister is on Ozempic for weight loss, my neighbor is on Wegovy, and a pharmacist told me they are the same drug. So why do they have different names?” As of September 2026, that question is being typed into search engines more than almost any other medicine query, and the surge has concrete triggers: an oral semaglutide tablet approved for weight management late last year, a run of follow-up studies showing how quickly weight returns after stopping, and the formal end of the shortage that had allowed compounded copies.

The pharmacist was right about the chemistry and incomplete about the rest. Same molecule, different labels, different trial populations, different maximum strengths, and a very different story about what each was actually tested to do. The gap between those two facts is where most of the confusion, and most of the viral claims, live.

What follows is the version a careful clinician would give you if the appointment ran long enough.

Why is everyone asking about Ozempic for weight loss right now?

Search interest in Ozempic for weight loss has outrun almost every other medicine query for three years running, and the reason is partly linguistic. Ozempic became the household word for an entire drug class, the way one brand of tissue stands in for all of them. People say Ozempic when they mean semaglutide, when they mean Wegovy, sometimes when they mean a completely different molecule.

That shorthand hides a real distinction. Ozempic is approved in the United States to help manage type 2 diabetes, to lower cardiovascular risk in adults who have diabetes and heart disease, and, since 2025, to slow kidney disease in that same group. Wegovy contains the identical active ingredient but carries a label for chronic weight management. When a clinician prescribes Ozempic to someone who does not have diabetes, that is off-label prescribing: legal, common and in this case backed by a large evidence base, yet still outside what the regulator reviewed for that purpose.

Three things are keeping the topic hot. The arrival of an oral semaglutide tablet approved for weight management has revived the question of which product is which. A steady stream of follow-up data on what happens after people stop has fed viral posts about rebound weight gain. And the end of a years-long shortage changed the legal status of compounded copies, which pushed many people back toward asking their own doctors what they should actually be taking.

This article walks through the molecule, the mechanism, the trials and the trade-offs in plain language. Where the evidence is strong, we say so. Where it thins out, we say that too.

What changed recently in the semaglutide story

A few dated milestones explain why the ground keeps shifting.

In December 2017 the FDA approved Ozempic (semaglutide injection) for adults with type 2 diabetes. Weight loss showed up as a secondary finding in those diabetes trials, typically a few kilograms more than comparison treatments, and clinicians noticed. In June 2021 the agency approved the same molecule at a higher maintenance strength under the name Wegovy for chronic weight management in adults with obesity, or overweight plus a weight-related condition. Adolescents aged 12 and older were added in December 2022.

November 2023 brought the SELECT trial, published in the New England Journal of Medicine and indexed on PubMed. Among 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide cut major adverse cardiovascular events (heart attack, stroke or cardiovascular death) by a relative 20 percent over roughly 40 months. In March 2024 the FDA added that cardiovascular risk reduction to the Wegovy label, the first time a weight-management medicine had earned one.

In January 2025 Ozempic gained an indication to reduce the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease. In February 2025 the FDA declared the semaglutide shortage resolved, which ended the temporary allowance that had let compounding pharmacies produce copies. In August 2025 Wegovy received accelerated approval for metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease with inflammation and scarring. Late in 2025 an oral semaglutide tablet was approved for weight management, the first GLP-1 pill with that indication.

None of those steps changed Ozempic’s own label to include weight loss. The off-label question remains exactly that.

What is the active ingredient in Ozempic?

The active ingredient in Ozempic is semaglutide, and the same is true of Wegovy and Rybelsus. Three brand names, one molecule, three different approvals.

Semaglutide is a GLP-1 receptor agonist. GLP-1, short for glucagon-like peptide-1, is a hormone your small intestine releases within minutes of eating; it tells the pancreas to release insulin, tells the stomach to slow down and tells the brain that food has arrived. Your own GLP-1 lasts only a minute or two in the bloodstream before an enzyme breaks it down, which is why it never worked as a medicine on its own.

Chemists solved that by altering the hormone. Semaglutide is about 94 percent identical to human GLP-1, with two amino acid swaps that protect it from the enzyme and a fatty acid side chain that lets it bind to albumin, the main protein in blood plasma. Hitching a ride on albumin stretches the half-life to roughly one week, which is why the injectable forms are taken weekly rather than several times a day.

Rybelsus packages the same molecule as a tablet. Peptides are normally digested like food, so the tablet includes an absorption enhancer that briefly changes the chemistry around the pill in the stomach, letting a small fraction cross the stomach lining. That fraction is small and variable, which is why its weight effects in trials have been more modest than the injections.

Knowing it is one ingredient dispels a persistent confusion: there is no “diabetes semaglutide” and “weight-loss semaglutide.” The body does not read the label on the pen. What differs is the approved use, the approved strengths, the delivery route and, in practice, who gets covered for which.

How does semaglutide work for weight loss?

Ask people on semaglutide what changed and most describe the same thing: the food noise went quiet. That is not a marketing phrase; it maps onto what the molecule does in the brain.

GLP-1 receptors sit in the hypothalamus and brainstem, the regions that set hunger and fullness. Semaglutide activates them directly, which lowers appetite, reduces the pull of high-fat and sweet foods and makes a smaller meal feel finished. In controlled feeding studies, people on semaglutide ate roughly a quarter to a third fewer calories at a buffet meal without being told to restrict anything.

A second effect happens in the stomach. Semaglutide slows gastric emptying, the rate at which food moves from the stomach into the intestine, so fullness lingers after eating. This effect is strongest in the early weeks and fades somewhat with continued use, which is one reason nausea tends to ease over time.

A third effect sits in the pancreas. Semaglutide prompts insulin release only when blood glucose is high and dampens glucagon, the hormone that tells the liver to release stored sugar. Because it works in a glucose-dependent way, it rarely drives blood sugar dangerously low on its own; that risk rises mainly when it is combined with insulin or sulfonylureas.

What semaglutide does not do is burn fat directly or raise metabolic rate. Weight comes off because energy intake falls and stays lower for as long as the medicine is present. That explains both its strength, since it targets the biological drive that undermines most diets, and its central limitation, which is that the drive returns when the drug is withdrawn.

Why is Ozempic prescribed off-label for weight loss?

Off-label prescribing means using an approved medicine for a condition, population or purpose not listed on its FDA label. It is legal in the United States, it is routine in many fields, and it carries one obligation: the clinician, not the regulator, takes responsibility for weighing benefit and risk for that particular patient.

Several forces made Ozempic the off-label choice for weight. The first was timing. Ozempic reached pharmacies in early 2018; Wegovy did not arrive until mid-2021, and within months it was in shortage. Clinicians who had watched patients with diabetes lose weight on Ozempic reasoned, correctly, that the molecule was identical. The second was coverage. Many insurance plans excluded weight-management medicines entirely while covering diabetes medicines, so a diagnosis of prediabetes or insulin resistance sometimes became the practical route to treatment. The third was supply itself: when one product was unavailable, prescribers switched to the other.

The evidence supporting that reasoning is reasonably strong, because the pivotal Wegovy trials studied the same molecule in people without diabetes. The gap is in the details. Ozempic’s approved strengths top out below Wegovy’s, so someone on Ozempic may not reach the exposure that produced the headline trial results. The product also has not been studied by its manufacturer specifically for weight management under its own name, so safety monitoring, patient materials and instructions were written for diabetes.

Guidelines from major obesity and endocrine societies recognize semaglutide as a first-line option for people who meet criteria for weight-management medication, but they point to the product approved for that purpose. Whether to use Ozempic instead, and whether medication is appropriate at all, is a decision for the treating clinician who knows your history, your other medicines and your goals.

Wegovy vs Ozempic: what is actually different?

Side by side, the differences are administrative more than pharmacological, with one exception that matters for results.

Feature	Ozempic	Wegovy	Rybelsus
Active ingredient	Semaglutide	Semaglutide	Semaglutide
Form	Weekly injection pen	Weekly injection pen; oral tablet approved late 2025	Daily tablet
FDA-approved uses	Type 2 diabetes; cardiovascular and kidney risk reduction in adults with diabetes	Chronic weight management from age 12; cardiovascular risk reduction in adults with overweight or obesity and heart disease; MASH	Type 2 diabetes
Year first approved	2017	2021	2019
Weight loss in pivotal trials	About 4–6 kg more than comparators in diabetes trials (secondary outcome)	Mean 14.9% vs 2.4% placebo at 68 weeks in adults without diabetes	About 2–4 kg more than comparators in diabetes trials
Approved for weight management?	No (off-label)	Yes	No

The exception is maintenance strength. Wegovy’s label permits a higher top strength than Ozempic’s, and the STEP trials that produced the 15 percent average were run at that higher exposure. Someone using Ozempic for weight loss may plateau earlier. Published diabetes trial data for Ozempic show smaller average losses, though those participants also had diabetes, a condition that blunts weight loss with every drug in this class.

Pen design and injection technique are essentially the same, the molecule’s side-effect profile is the same, and the contraindications are the same. The label on the box determines what the regulator reviewed, what the manufacturer can promote and, in most cases, what an insurer will pay for. Those are not trivial differences, but they are not chemical ones either.

How does Wegovy help you lose weight?

The clearest answer comes from STEP 1, published in 2021. Researchers enrolled 1,961 adults with obesity, or overweight plus a weight-related condition, none of whom had diabetes. Everyone received lifestyle counseling. Two-thirds were randomized to weekly semaglutide, one-third to placebo, for 68 weeks.

The semaglutide group lost an average of 14.9 percent of starting body weight; the placebo group lost 2.4 percent. For a person starting at 100 kg (220 lb), that is roughly 15 kg (33 lb) versus 2.4 kg (5 lb). About 86 percent of people on semaglutide lost at least 5 percent, 69 percent lost at least 10 percent and half lost 15 percent or more. Roughly one in three lost 20 percent, a figure previously seen mainly with bariatric surgery.

Weight was not the only change. Waist circumference, blood pressure, fasting glucose, triglycerides and markers of inflammation all improved more in the semaglutide group, and participants reported better physical function. A subset scanned with DEXA, a body-composition X-ray, lost both fat and lean mass; around 60 percent of the weight lost was fat and 40 percent lean tissue, a proportion similar to diet-induced weight loss, though the absolute lean loss was larger because total loss was larger.

The trajectory matters as much as the endpoint. Weight fell steadily for about a year and then flattened. That plateau is not failure; it is the body settling at a new balance between appetite and intake. In STEP 5, which ran for two years, the loss held at about 15 percent through week 104 for people who stayed on treatment.

So Wegovy helps you lose weight by lowering appetite enough that sustained caloric restriction becomes tolerable, and it helps keep weight off only for as long as it keeps doing that.

What the evidence actually says, graded by strength

Not every claim about semaglutide rests on the same footing. Here is how the main ones rank.

Strong, from randomized controlled trials. Average weight loss of roughly 15 percent over 68 weeks in adults without diabetes, and roughly 10 percent in adults with type 2 diabetes, comes from the STEP program, thousands of participants across multiple double-blind trials. Reduction in major cardiovascular events in people with existing heart disease comes from SELECT, more than 17,000 people followed for over three years. Improvements in blood pressure, A1C and lipids are consistent across trials. Gastrointestinal side effects as the dominant tolerability issue are equally well established.

Moderate, from trials with limits or shorter follow-up. Weight regain after stopping is supported by the STEP 1 extension and STEP 4, which were not designed primarily to study withdrawal but showed it clearly. Benefit in heart failure with preserved ejection fraction, sleep apnea and fatty liver disease comes from dedicated trials, each informative but smaller than STEP 1 or SELECT.

Weak or emerging, from observational data. Lower rates of alcohol use, reduced cravings for nicotine, and lower dementia or cancer incidence have appeared in database studies comparing people who happened to take GLP-1 medicines with people who did not. Those designs cannot separate the drug from the kind of person who gets prescribed it. Randomized trials are under way.

Expert opinion. Advice on protein intake and resistance exercise to protect lean mass, and on how long to continue treatment, reflects clinical consensus rather than trial evidence specific to semaglutide.

One honest gap deserves naming: no trial has yet followed people on semaglutide for a decade. SELECT’s three-plus years is the longest controlled safety window so far.

How quickly does Rybelsus work, and is it a weight-loss pill?

Rybelsus is semaglutide in a once-daily tablet, approved in September 2019 for blood sugar control in adults with type 2 diabetes. It is not approved for weight management, and the newer oral Wegovy tablet is a separate product with its own label.

Timing follows the pharmacology. Because semaglutide has a half-life of about a week, blood levels build gradually and reach a steady state after roughly four to five weeks of daily tablets. People often notice reduced appetite within the first couple of weeks, and fasting glucose begins to drift down over the same period. In the PIONEER trials that supported approval, the full effect on A1C, a three-month average of blood glucose, was measured at 26 weeks.

Weight loss with Rybelsus in those trials was real but modest, typically a few kilograms more than placebo or comparison drugs, and the participants all had diabetes. Head-to-head, the injectable forms deliver more semaglutide to the bloodstream more consistently, which is the main reason their weight results are larger.

Absorption is also fussy. The label calls for taking the tablet on an empty stomach and waiting before food, drink or other medicines, because anything else in the stomach sharply reduces how much gets through. Skip that routine regularly and the medicine may underperform, which is worth raising with a prescriber before concluding it does not work.

For someone who already has type 2 diabetes and strongly prefers to avoid injections, Rybelsus is a reasonable conversation to have. For someone whose primary goal is weight loss, the trial evidence points toward the products studied for that purpose. Either way, the choice belongs to the clinician who manages your care.

Ozempic side effects: what is common and what is rare

Semaglutide’s side-effect profile is predictable, and predictability is useful.

Gastrointestinal effects dominate. In STEP 1, nausea affected about 44 percent of people on semaglutide versus 17 percent on placebo; diarrhea, vomiting and constipation followed. Most episodes were mild to moderate, clustered in the early months and eased as the body adapted. Around 7 percent of people stopped because of gastrointestinal symptoms, compared with 3 percent on placebo. Clinicians manage this with smaller, slower meals, less fat and alcohol, and a gradual introduction schedule that the prescriber controls.

Gallbladder problems, including gallstones, occur more often with any rapid weight loss, and trials showed a small excess with semaglutide. Pancreatitis, inflammation of the pancreas, is rare but serious; its hallmark is severe, persistent abdominal pain that may radiate to the back. Delayed stomach emptying can, uncommonly, become severe enough to cause persistent vomiting or bowel obstruction, and that language was added to US labels in 2023.

The boxed warning concerns thyroid C-cell tumors. Rodents given GLP-1 agonists developed them; whether humans do is unknown, and surveillance to date has not confirmed a signal. The drugs are nonetheless not prescribed to people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Lean-mass loss, facial volume loss (“Ozempic face”) and hair shedding are consequences of substantial weight loss by any method rather than drug toxicity. Low blood sugar is uncommon unless insulin or a sulfonylurea is also on board. Reports of suicidal thoughts prompted FDA and European reviews in 2024; neither found evidence of a causal link, though labels still advise monitoring mood.

Why am I not losing weight on Ozempic?

Roughly one person in seven in STEP 1 lost less than 5 percent on semaglutide. Non-response is real, and so are several fixable explanations.

The product may be the issue. Ozempic’s approved strengths are lower than Wegovy’s, and many people plateau before reaching the exposure used in the weight trials. Someone prescribed Ozempic off-label who stalls early may simply be at the ceiling of that product, which is a conversation for the prescriber, not a reason to adjust anything yourself.

Time may be the issue. Average loss in the trials was gradual; most of the 15 percent accrued over the first year. Three months in, with a few percent lost, is on track rather than behind.

Diabetes changes expectations. Every drug in this class produces smaller losses in people with type 2 diabetes, around 10 percent rather than 15 in the semaglutide trials, likely because of insulin resistance and the weight-promoting effects of other diabetes medicines.

Other medicines matter. Some antidepressants, antipsychotics, steroids and insulin itself push weight up and can mask the drug’s effect. Untreated sleep apnea, hypothyroidism and chronic high stress do similar work.

Intake can creep back. Appetite suppression lowers the drive to eat but does not make calorie-dense liquids, grazing or alcohol disappear. People who did best in trials typically kept a basic food log and some regular physical activity.

Biology varies, too. Genetic differences in GLP-1 receptor signaling, gut hormone profiles and body-weight set points mean a minority will not respond meaningfully to this molecule and may do better with a different class. Identifying that early saves months. A prescriber can review all of these with you and decide whether to continue, switch or add.

What happens when you stop Ozempic?

The honest answer is that most of the weight comes back, and the follow-up studies tell us roughly how much and how fast.

In the STEP 1 extension, researchers tracked participants for a year after the trial ended and treatment stopped. People who had lost an average of 17 percent on semaglutide regained about two-thirds of it within 12 months, finishing roughly 5 to 6 percent below their starting weight. Blood pressure, lipids and A1C that had improved on treatment drifted back toward baseline over the same period.

STEP 4 was designed to make the comparison cleaner. Everyone took semaglutide for 20 weeks and lost about 11 percent. Then half were switched, blind, to placebo. Over the next 48 weeks the group that continued lost a further 8 percent; the group switched to placebo regained about 7 percent.

What happens in the body is a straightforward reversal. Within about five weeks of the last injection, semaglutide has largely cleared. Appetite returns, often with notable intensity, because weight loss itself lowers leptin and raises ghrelin, hormones that signal energy deficit and hunger. Gastric emptying returns to its previous speed, so meals feel less filling. Nothing in that sequence is damage; it is the same physiology that defeats most diets, no longer being overridden.

This is why obesity-medicine guidelines describe semaglutide as a long-term treatment for a chronic condition, in the same category as blood-pressure medicines, rather than a course to complete. Whether to stop, taper, pause or switch is a decision to make with the prescriber, who may also want to monitor blood sugar, blood pressure and mood during the transition. Stopping abruptly on your own because of side effects or a plateau is where the worst rebound stories tend to begin.

Common myths about Ozempic for weight loss

Viral claims travel faster than trial data. A few that deserve correction:

• “Ozempic is a weight-loss drug.” It is a diabetes drug whose molecule is also sold, under a different name and label, for weight management. The distinction decides what was tested, what is covered and what the instructions assume.
• “It melts fat.” Semaglutide does not increase fat burning or metabolic rate. It reduces appetite, so intake falls. Body fat declines because of the resulting energy deficit.
• “Take it for a few months to reset your metabolism.” The STEP extension data show the opposite: appetite and weight return once the drug clears. There is no evidence of a lasting reset.
• “It destroys muscle.” Lean mass falls with any substantial weight loss. In STEP 1, the proportion lost as lean tissue was similar to that seen with dieting. Protein intake and resistance training are the standard countermeasures.
• “Compounded semaglutide is the same thing.” Compounded products are not FDA-approved, are not reviewed by the regulator for purity or potency, and since the shortage was declared over in February 2025 most mass compounding is no longer permitted. The FDA has logged dosing errors and hospitalizations linked to them. They are not for self-purchase or self-use.
• “It causes suicidal thoughts.” Regulators in the US and Europe reviewed the reports in 2024 and found no evidence of a causal link. Labels still advise monitoring, which is reasonable caution rather than a confirmed effect.
• “If thin people use it, it must be safe for anyone.” The trials enrolled people meeting BMI criteria. Safety and benefit outside those groups have not been studied, and risks such as gallstones and nutrient deficiency rise when there is little weight to lose.

Correcting these is not pedantry. Each one shapes a decision someone will make at a kitchen table, and each is answered by data that already exist.

When to see a doctor

Anyone considering semaglutide for weight should begin with a clinician, not a pen. Beyond that, some situations call for prompt contact.

Seek urgent care, or emergency services if severe, for:

• Severe, persistent abdominal pain, with or without vomiting, especially if it spreads to the back: possible pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools: possible gallbladder or bile duct problems.
• Repeated vomiting, inability to keep fluids down, or no bowel movement with a swollen, painful abdomen: possible severe gastroparesis or obstruction.
• Symptoms of low blood sugar, such as shakiness, sweating, confusion or fainting, particularly if you also take insulin or a sulfonylurea.
• A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath: the label asks for evaluation.
• Sudden changes in vision, which may signal rapid glucose shifts affecting the retina in people with diabetes.
• New or worsening depressed mood, or any thoughts of self-harm.
• Signs of a serious allergic reaction: swelling of the face or throat, hives, difficulty breathing.
• Decreased urination with dizziness, which can indicate dehydration and kidney strain after vomiting or diarrhea.

Book a routine appointment, rather than an urgent one, if nausea or constipation persists beyond the first weeks, if weight loss stalls for more than two or three months, if you are planning pregnancy (semaglutide should be stopped well ahead of conception under medical guidance), if you are scheduled for surgery or anesthesia, or if you are thinking about stopping for any reason.

Never adjust strength, skip ahead, double up after a missed injection or switch between semaglutide products on your own. Every one of those decisions sits with the prescribing clinician, who can weigh your history, your other medicines and your goals in a way no article can.

Frequently asked questions

What is the active ingredient in Ozempic?

Semaglutide is the active ingredient in Ozempic, and also in Wegovy and Rybelsus. It is a laboratory-modified version of GLP-1, a gut hormone that signals fullness, slows stomach emptying and prompts insulin release when blood sugar is high. The modifications let it last about a week in the body instead of a couple of minutes, which is why the injectable products are taken weekly.

How does Wegovy help you lose weight?

Wegovy lowers appetite by activating GLP-1 receptors in the brain’s hunger centers, slows stomach emptying so meals feel more filling, and reduces cravings for calorie-dense foods. In the 68-week STEP 1 trial, adults without diabetes lost an average of 14.9 percent of body weight versus 2.4 percent on placebo. The effect persists only while the medicine is taken.

How quickly does Rybelsus work?

Rybelsus, the daily semaglutide tablet for type 2 diabetes, reaches steady blood levels after about four to five weeks. Many people notice reduced appetite within the first weeks, and fasting glucose begins to fall over the same period; its full A1C effect in trials was measured at 26 weeks. Weight loss with Rybelsus is modest and it is not approved for weight management.

What does going off Ozempic do to your body?

Within about five weeks of the last injection semaglutide has mostly cleared, appetite returns and stomach emptying speeds back up. Follow-up studies show most people regain roughly two-thirds of lost weight within a year, and blood pressure, lipids and blood sugar drift back toward their earlier levels. No lasting harm is documented; the underlying biology simply resumes. Any decision to stop should be made with the prescriber.

Is Wegovy vs Ozempic just a branding difference?

Mostly, but not entirely. Both contain semaglutide, use similar pens and share the same side effects and contraindications. Wegovy is approved for weight management and cardiovascular risk reduction in people without diabetes, while Ozempic is approved for type 2 diabetes. Wegovy’s label also permits a higher maintenance strength, and the large weight-loss trials were run at that higher exposure.

How does semaglutide work in the brain?

Semaglutide crosses into the hypothalamus and brainstem, where GLP-1 receptors regulate hunger and satiety. Activating them reduces the drive to eat, dulls the reward signal from high-fat and sweet foods and makes smaller portions feel sufficient. In feeding studies, people on semaglutide ate roughly 24 to 35 percent fewer calories at a free-choice meal without conscious restriction. The effect reverses when the drug is withdrawn.

What are the most common Ozempic side effects?

Nausea is the most common, affecting roughly 44 percent of trial participants on semaglutide compared with 17 percent on placebo, followed by diarrhea, vomiting and constipation. Most symptoms are mild, appear early and fade with time. Rarer but serious problems include gallbladder disease, pancreatitis, severe delayed stomach emptying and, in people also using insulin or sulfonylureas, low blood sugar.

Can a doctor legally prescribe Ozempic for weight loss without diabetes?

Yes. Off-label prescribing is legal in the United States and common across medicine. The clinician takes responsibility for judging that the evidence supports the use, and for Ozempic that evidence comes largely from trials of the same molecule sold as Wegovy. Whether it is appropriate for a given person, and whether the approved product would serve better, is the prescriber’s call.

Why am I not losing weight on Ozempic?

Common reasons include being on a product whose approved strengths are lower than those used in weight-loss trials, not enough time elapsed, having type 2 diabetes, taking other medicines that promote weight gain, calorie intake creeping back through liquids or grazing, and genuine biological non-response, which affected about one in seven trial participants. A prescriber can sort through these and decide whether to continue, switch or add.

Is compounded semaglutide safe to buy online?

Compounded semaglutide is not FDA-approved, has not been reviewed by the regulator for purity, potency or safety, and the temporary shortage allowance that permitted mass compounding ended in February 2025. The FDA has received reports of dosing errors and hospitalizations linked to these products. They are not for sale to the public for self-use, and anyone offered them should speak to a licensed clinician instead.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.